Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,938 |
Last balance in matching sequence
After 2026-10-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 413 · Balance 10,351 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 413 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 24,587 · Balance 34,525 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Sale · Disposed 15,843 · Balance 18,682 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 8,744 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 66,573 |
Reported balance
After 2026-10-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-10-01 · Exercise / conversion · Disposed 413 · Balance 66,573 F11: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 41,986 |
Reported balance
After 2026-10-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-02 · Exercise / conversion · Disposed 24,587 · Balance 41,986 F11: Fully exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,147 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,147 F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 20,570 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 20,570 F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 40,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 40,000 F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 34,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 34,000 F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 10,000 F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2026 Filed Feb 13, 2026 21:25 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 20,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-051492 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 20,570 F2 · ownership.nature: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. Read SEC document |
| January 08, 2026 Filed Feb 13, 2026 21:25 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 20,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-051492 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 39,147 F1 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 135 | $79.78 | $10,770.30 |
DisclosureSEC source: 0001193125-25-307251 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,179 F7 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F8 · price: The closing price on December 1, 2025 was used to calculate the withholding obligation. F1 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0001193125-25-307251 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,986 Underlying: Common Stock · 20,000 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307251 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,314 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F1 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 205 | $79.78 | $16,354.90 |
DisclosureSEC source: 0001193125-25-307251 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,109 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F1 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $79.52 | $1,590,490.00 |
DisclosureSEC source: 0001193125-25-307251 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,904 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.81 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $8.27 | $165,400.00 |
DisclosureSEC source: 0001193125-25-307251 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0001193125-25-267542 · ownership.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 261,986 Underlying: Common Stock · 20,000 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $73.99 | $1,479,816.00 |
DisclosureSEC source: 0001193125-25-267542 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,904 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $74.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $8.27 | $165,400.00 |
DisclosureSEC source: 0001193125-25-267542 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 18,014 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · derivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,986 Underlying: Common Stock · 18,014 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 1,986 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,986 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,647 | $85.58 | $226,519.14 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,904 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.41 to $85.79 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 16,394 | $85.06 | $1,394,411.34 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,551 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.41 to $85.40 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 959 | $83.73 | $80,301.29 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,945 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.23 to $84.16 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 18,014 | $8.27 | $148,975.78 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 1,986 | $5.05 | $10,029.30 |
DisclosureSEC source: 0001193125-25-230435 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 233 | $71.38 | $16,631.54 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · nonDerivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,904 F8 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F9 · price: The closing price on September 2, 2025 was used to calculate the withholding obligation. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · derivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,986 Underlying: Common Stock · 20,000 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 228 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,137 F7 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 228 | $71.38 | $16,274.64 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,909 F5 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025. F6 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,930 | $70.84 | $349,220.99 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,681 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.72 to $71.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 15,070 | $70.38 | $1,060,607.01 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,611 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.715 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $5.05 | $101,000.00 |
DisclosureSEC source: 0001193125-25-196315 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 35,007 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · derivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,986 Underlying: Common Stock · 35,007 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,714 | $69.70 | $119,467.17 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,681 F6 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.48 to $69.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,428 | $68.52 | $371,952.07 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,395 F6 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.17 to $69.13 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 27,865 | $67.53 | $1,881,818.19 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,823 F6 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.17 to $68.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 35,007 | $5.05 | $176,785.35 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 473 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-097374 · ownership.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,993 Underlying: Common Stock · 473 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 473 | $73.44 | $34,737.31 |
DisclosureSEC source: 0000950170-25-097374 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,705 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.47 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 473 | $5.05 | $2,388.65 |
DisclosureSEC source: 0000950170-25-097374 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 4,315 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-097374 · ownership.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,466 Underlying: Common Stock · 4,315 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,315 | $73.48 | $317,053.69 |
DisclosureSEC source: 0000950170-25-097374 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,705 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 4,315 | $5.05 | $21,790.75 |
DisclosureSEC source: 0000950170-25-097374 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 03, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 40,000 F4 · kind: Transfer of shares without consideration to the SNM 2025 Grantor Retained Annuity Trust. F5 · ownership.nature: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Read SEC document |
| July 03, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 59,717 F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 205 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-094120 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,781 Underlying: Common Stock · 205 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 205 | $73.45 | $15,057.72 |
DisclosureSEC source: 0000950170-25-094120 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,705 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.62 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 205 | $5.05 | $1,035.25 |
DisclosureSEC source: 0000950170-25-094120 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 12, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,024 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 99,717 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| June 12, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,024 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-103324 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,681 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · derivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,986 Underlying: Common Stock · 20,000 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,811 | $80.77 | $146,268.86 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,705 F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.585 to $81.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,246 | $79.89 | $498,967.33 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,516 F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.5725 to $80.535 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,191 | $78.87 | $488,311.41 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,762 F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $79.5675 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,752 | $77.91 | $448,138.90 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,953 F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.515 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 20,000 | $5.05 | $101,000.00 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,705 F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 888 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,705 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.